The weight loss drug market, driven by GLP-1 therapies, is expected to grow to $130-150 billion by 2035. The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors targeted exposure to this expanding sector, including major pharmaceutical companies like Novo Nordisk and Eli Lilly, as well as biotech and healthcare service firms. Innovations are broadening beyond current leaders to include oral drugs, genetic treatments, and muscle-preserving therapies, signaling diverse growth opportunities. THNR tracks the VettaFi Weight Loss Drug & Treatment Index and focuses on the entire clinical and digital ecosystem supporting obesity treatment.
Novo Nordisk shares dropped 2.5% after Deutsche Bank's weekly prescription data tracker indicated a continued slowdown in the oral version of its weight-loss drug, Wegovy, in the US. This slowdown is significant because the oral formulation was seen ...
UBS has reiterated its overweight stance on European pharmaceuticals, viewing the sector as a more stable investment than artificial intelligence amid a slowing market. The bank highlights improving earnings, low valuations, and lighter ownership as ...
Novo Nordisk is rated a BUY as its oral Wegovy drug rapidly expands the obesity treatment market in the U.S., with over 3 million prescriptions in five months, mostly from patients new to GLP-1 treatments. This strong demand has led management to rai...
